Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 29 | 2025 | 962 | 3.570 |
Why?
|
| Cell- and Tissue-Based Therapy | 9 | 2025 | 154 | 2.420 |
Why?
|
| T-Lymphocytes | 24 | 2025 | 1790 | 2.330 |
Why?
|
| Genetic Therapy | 4 | 2025 | 726 | 1.800 |
Why?
|
| Receptors, Antigen, T-Cell | 15 | 2025 | 503 | 1.670 |
Why?
|
| Herpesvirus 4, Human | 7 | 2025 | 646 | 1.650 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2025 | 157 | 1.410 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2025 | 1264 | 1.380 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2025 | 294 | 1.380 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2024 | 218 | 1.340 |
Why?
|
| Hematologic Neoplasms | 4 | 2025 | 315 | 1.330 |
Why?
|
| Antigens, CD19 | 10 | 2024 | 191 | 1.330 |
Why?
|
| Health Services Accessibility | 7 | 2025 | 701 | 1.100 |
Why?
|
| Killer Cells, Natural | 4 | 2018 | 344 | 1.010 |
Why?
|
| Lymphoma | 4 | 2025 | 331 | 0.950 |
Why?
|
| Leukemia | 2 | 2024 | 375 | 0.800 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 180 | 0.760 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2025 | 580 | 0.700 |
Why?
|
| Immunotherapy | 4 | 2025 | 767 | 0.700 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2024 | 276 | 0.640 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 134 | 0.600 |
Why?
|
| Poverty | 1 | 2023 | 456 | 0.600 |
Why?
|
| Tumor Microenvironment | 3 | 2024 | 701 | 0.590 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2023 | 849 | 0.560 |
Why?
|
| Humans | 58 | 2025 | 131967 | 0.510 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 267 | 0.490 |
Why?
|
| Immune Evasion | 1 | 2015 | 39 | 0.470 |
Why?
|
| Receptors, KIR | 1 | 2015 | 11 | 0.470 |
Why?
|
| Smad Proteins | 1 | 2015 | 45 | 0.470 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2019 | 468 | 0.450 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2015 | 58 | 0.440 |
Why?
|
| Lymphoma, B-Cell | 3 | 2023 | 149 | 0.430 |
Why?
|
| Siblings | 1 | 2015 | 204 | 0.430 |
Why?
|
| Patient Safety | 1 | 2019 | 447 | 0.420 |
Why?
|
| Virus Activation | 1 | 2014 | 86 | 0.420 |
Why?
|
| Cytomegalovirus | 1 | 2015 | 259 | 0.420 |
Why?
|
| Neoplasms | 6 | 2025 | 2965 | 0.410 |
Why?
|
| Cytomegalovirus Infections | 1 | 2015 | 225 | 0.390 |
Why?
|
| Child | 23 | 2025 | 26332 | 0.390 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 462 | 0.380 |
Why?
|
| Young Adult | 15 | 2025 | 10108 | 0.380 |
Why?
|
| Adolescent | 20 | 2025 | 21008 | 0.360 |
Why?
|
| Lymphoma, T-Cell | 2 | 2024 | 64 | 0.340 |
Why?
|
| CD5 Antigens | 2 | 2024 | 33 | 0.330 |
Why?
|
| Antigens, Neoplasm | 3 | 2021 | 405 | 0.310 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2020 | 163 | 0.280 |
Why?
|
| Neutropenia | 2 | 2025 | 205 | 0.260 |
Why?
|
| Minority Groups | 2 | 2024 | 256 | 0.230 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2025 | 66 | 0.230 |
Why?
|
| Male | 18 | 2025 | 65357 | 0.220 |
Why?
|
| Science | 1 | 2025 | 36 | 0.220 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 91 | 0.220 |
Why?
|
| Technology | 1 | 2025 | 69 | 0.220 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2017 | 694 | 0.220 |
Why?
|
| Hematology | 1 | 2024 | 42 | 0.220 |
Why?
|
| Adult | 15 | 2025 | 31734 | 0.220 |
Why?
|
| Rituximab | 1 | 2024 | 174 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 162 | 0.190 |
Why?
|
| Female | 19 | 2025 | 71316 | 0.190 |
Why?
|
| Proteome | 1 | 2025 | 288 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 164 | 0.190 |
Why?
|
| Bone Marrow Diseases | 1 | 2022 | 45 | 0.190 |
Why?
|
| Organ Transplantation | 1 | 2024 | 172 | 0.190 |
Why?
|
| Graft vs Host Disease | 2 | 2019 | 680 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 544 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 1000 | 0.180 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 153 | 0.180 |
Why?
|
| Transplantation, Homologous | 3 | 2025 | 671 | 0.180 |
Why?
|
| Antigens, CD7 | 2 | 2018 | 11 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 359 | 0.160 |
Why?
|
| Child, Preschool | 9 | 2025 | 15066 | 0.160 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 325 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2021 | 178 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 460 | 0.150 |
Why?
|
| Cytokines | 4 | 2022 | 1354 | 0.150 |
Why?
|
| Regenerative Medicine | 1 | 2019 | 39 | 0.150 |
Why?
|
| Vaccinia virus | 1 | 2019 | 50 | 0.150 |
Why?
|
| Pyridazines | 1 | 2019 | 54 | 0.150 |
Why?
|
| Antibodies, Viral | 1 | 2025 | 1174 | 0.140 |
Why?
|
| Imidazoles | 1 | 2019 | 222 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 361 | 0.130 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 69 | 0.130 |
Why?
|
| United States | 4 | 2025 | 11827 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 989 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1281 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 2017 | 163 | 0.120 |
Why?
|
| Transplantation Conditioning | 1 | 2018 | 329 | 0.120 |
Why?
|
| Graft Rejection | 1 | 2019 | 562 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5298 | 0.110 |
Why?
|
| Infant | 5 | 2025 | 13332 | 0.110 |
Why?
|
| B-Lymphocytes, Regulatory | 1 | 2014 | 2 | 0.110 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2014 | 23 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2025 | 3708 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 213 | 0.100 |
Why?
|
| Vaccination | 1 | 2019 | 1043 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2015 | 772 | 0.100 |
Why?
|
| Immunologic Memory | 1 | 2014 | 202 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2025 | 13011 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2088 | 0.090 |
Why?
|
| Phosphorylation | 1 | 2015 | 1572 | 0.090 |
Why?
|
| Middle Aged | 8 | 2025 | 28911 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3453 | 0.090 |
Why?
|
| Leukocytosis | 1 | 2011 | 46 | 0.090 |
Why?
|
| Genomics | 1 | 2019 | 1630 | 0.080 |
Why?
|
| Lymphocyte Activation | 3 | 2019 | 681 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2013 | 517 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2013 | 437 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2024 | 798 | 0.080 |
Why?
|
| Biomarkers | 2 | 2017 | 3415 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2011 | 92 | 0.080 |
Why?
|
| Aged | 6 | 2025 | 21279 | 0.080 |
Why?
|
| Infant, Premature, Diseases | 1 | 2011 | 255 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2025 | 17703 | 0.070 |
Why?
|
| Down Syndrome | 1 | 2011 | 233 | 0.070 |
Why?
|
| Animals | 8 | 2024 | 34460 | 0.070 |
Why?
|
| Myeloid Cells | 2 | 2018 | 114 | 0.070 |
Why?
|
| Mice | 6 | 2022 | 18504 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2017 | 4693 | 0.060 |
Why?
|
| Prognosis | 3 | 2025 | 4961 | 0.060 |
Why?
|
| Transduction, Genetic | 2 | 2017 | 279 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2024 | 1239 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2019 | 2483 | 0.060 |
Why?
|
| Drug Industry | 1 | 2025 | 48 | 0.060 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 228 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 496 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 123 | 0.050 |
Why?
|
| Personnel Selection | 1 | 2024 | 79 | 0.050 |
Why?
|
| Mentors | 1 | 2025 | 161 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 157 | 0.050 |
Why?
|
| Career Choice | 1 | 2024 | 163 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2023 | 170 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2014 | 337 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 88 | 0.050 |
Why?
|
| Gene Expression | 2 | 2017 | 1503 | 0.050 |
Why?
|
| Informed Consent | 1 | 2025 | 343 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 222 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2023 | 551 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 812 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2022 | 579 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2022 | 314 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 419 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 179 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 182 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 2019 | 36 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 291 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 3708 | 0.040 |
Why?
|
| Retroviridae | 1 | 2019 | 182 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2019 | 240 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 115 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2022 | 550 | 0.040 |
Why?
|
| Registries | 1 | 2025 | 1598 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 250 | 0.040 |
Why?
|
| Viral Matrix Proteins | 1 | 2018 | 108 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 79 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 269 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2019 | 230 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 835 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 55 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 152 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2019 | 586 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 261 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 230 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 4684 | 0.030 |
Why?
|
| Apoptosis | 1 | 2022 | 1860 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2019 | 907 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 1487 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2015 | 46 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1261 | 0.030 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2014 | 5 | 0.030 |
Why?
|
| B7-1 Antigen | 1 | 2014 | 12 | 0.030 |
Why?
|
| B7-2 Antigen | 1 | 2014 | 16 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2014 | 18 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2014 | 31 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1101 | 0.030 |
Why?
|
| Pediatrics | 1 | 2024 | 1239 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 120 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2025 | 6522 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2014 | 80 | 0.030 |
Why?
|
| HLA-A2 Antigen | 1 | 2013 | 26 | 0.030 |
Why?
|
| WT1 Proteins | 1 | 2013 | 22 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 63 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 43 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 191 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2014 | 185 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2013 | 133 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 234 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 792 | 0.020 |
Why?
|
| Risk Factors | 1 | 2025 | 10998 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2013 | 542 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 838 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 782 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 677 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2963 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6922 | 0.010 |
Why?
|
| Mutation | 1 | 2019 | 6200 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2011 | 858 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 7577 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8604 | 0.010 |
Why?
|